Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Grade I Neuroendocrine Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Not applicableStudy completedNCT00899496
What this trial is testing

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Who this might be right for
Cancer
Wake Forest University Health Sciences 54
Testing effectiveness (Phase 2)Looking for participantsNCT07115043
What this trial is testing

Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)+6 more
AstraZeneca 120
Early research (Phase 1)Active Not RecruitingNCT02088645
What this trial is testing

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.

Who this might be right for
Thyroid Cancer, MedullaryNeuroendocrine Tumor of the Lung Grade 1 and 2Neuroendocrine Tumor of the Thymus Grade 1 and 2+1 more
University Hospital, Basel, Switzerland 24
Testing effectiveness (Phase 2)Looking for participantsNCT06472388
What this trial is testing

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsProgressionNeuroendocrine Tumor Grade 1+4 more
AC Camargo Cancer Center 100
Early research (Phase 1)Active Not RecruitingNCT04616248
What this trial is testing

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8+10 more
University of Southern California 14
Testing effectiveness (Phase 2)Looking for participantsNCT07357623
What this trial is testing

Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors

Who this might be right for
Pulmonary Neuroendocrine Tumor
Shanghai Chest Hospital 96
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802174
What this trial is testing

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Who this might be right for
SCLCSmall Cell CancerAdvanced Solid Tumor+1 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Study completedNCT01563354
What this trial is testing

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

Who this might be right for
Neuroendocrine Carcinoma of the Lung and Thymus
Novartis Pharmaceuticals 124
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Testing effectiveness (Phase 2)Study completedNCT00445965
What this trial is testing

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Who this might be right for
Brain and Central Nervous System TumorsIntraocular MelanomaLung Cancer+7 more
Memorial Sloan Kettering Cancer Center 78
Testing effectiveness (Phase 2)UnknownNCT00637637
What this trial is testing

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

Who this might be right for
Cancer
Oncology Institute of Southern Switzerland 60
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Testing effectiveness (Phase 2)Looking for participantsNCT06395402
What this trial is testing

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2
University of Iowa 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT04471727
What this trial is testing

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Who this might be right for
Small-Cell Lung CancerNeuroendocrine Carcinoma
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 232
Not applicableLooking for participantsNCT06981455
What this trial is testing

Life Following Excision of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine (NE) TumorsNeuroendocrine Tumor GEP Grade 1-3
Sunnybrook Health Sciences Centre 246
40